Century Therapeutics (IPSC) Stock Price, News & Analysis

Company Overview

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates. Early-stage programs include iPSC-derived NK cell candidates engineered for enhanced tumor targeting and persistence, alongside T cell programs incorporating novel receptor constructs. Century has established strategic collaborations with leading pharmaceutical partners to advance preclinical research and prepare select programs for clinical evaluation.

Founded in 2019 as a spin-out from the Wistar Institute and the University of Pennsylvania, Century Therapeutics is headquartered in Philadelphia. Since its inception, the company has built multidisciplinary teams across research, manufacturing and regulatory affairs. Century’s leadership brings experience from established biopharmaceutical companies and academic institutions, supporting its goal of delivering transformative cell therapies to patients worldwide.

Key Stats

• Today's Range: $2.25 to $2.36
• 50-Day Range: $2.02 to $2.94
• 52-Week Range: $0.44 to $3.04
• Volume: 745,802 shs
• Average Volume: 963,360 shs
• Market Capitalization: $422.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.25
• Consensus Rating: Hold

Century Therapeutics Stock Analysis - MarketRank™

Century Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 430th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Century Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Century Therapeutics has a consensus price target of $4.25, representing about 81.6% upside from its current price of $2.34.

Amount of Analyst Coverage

Century Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Century Therapeutics are expected to grow in the coming year, from ($0.63) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Century Therapeutics is -16.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Century Therapeutics is -16.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Century Therapeutics has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.37% of the float of Century Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Century Therapeutics has a short interest ratio ("days to cover") of 8.03.

Change versus previous month

Short interest in Century Therapeutics has recently increased by 6.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Century Therapeutics does not currently pay a dividend.

Dividend Growth

Century Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.48

News Sentiment

Century Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Century Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for IPSC on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

1 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $45,488.00 in company stock.

Percentage Held by Insiders

4.37% of the stock of Century Therapeutics is held by insiders.

Percentage Held by Institutions

50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IPSC Stock Analysis - Frequently Asked Questions

How have IPSC shares performed this year?

Century Therapeutics' stock was trading at $0.9948 at the start of the year. Since then, IPSC stock has increased by 135.2% and is now trading at $2.34.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) released its quarterly earnings results on Thursday, March, 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04.

When did Century Therapeutics IPO?

Century Therapeutics (IPSC) raised $200 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 10,550,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are Century Therapeutics' major shareholders?

Century Therapeutics' top institutional investors include Versant Venture Management LLC (6.75%), Cannon Global Investment Management LLC (0.03%), Quadrant Private Wealth Management LLC (0.01%) and Bank of New York Mellon Corp (0.01%). Insiders that own company stock include Brent Pfeiffenberger, Chad Cowan, Gregory Russotti, Douglas Carr and Adrienne Farid.
View institutional ownership trends.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Century Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Century Therapeutics investors own include The RMR Group (RMR), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IPSC
• CIK: 1850119
• Web: www.centurytx.com
• Phone: 267-817-5790
• Fax: N/A
• Employees: 170
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Century Therapeutics: $4.25
• High Price Target: $6.00
• Low Price Target: $2.00
• Potential Upside/Downside: +81.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.58 million
• Net Margins: N/A
• Pretax Margin: -8.84%
• Return on Equity: -1.43%
• Return on Assets: -1.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.97
• Quick Ratio: 5.97

Sales & Book Value

• Annual Sales: $109.16 million
• Price / Sales: 3.87
• Cash Flow: $0.01 per share
• Price / Cash Flow: 172.18
• Book Value: $1.82 per share
• Price / Book: 1.29

Miscellaneous

• Outstanding Shares: 180,350,000
• Free Float: 172,473,000
• Market Cap: $422.02 million
• Optionable: Optionable
• Beta: 1.55